|
Plasma p-tau231: A Precise Early Biomarker for Alzheimer's Disease?
hits:40 Date:05/21/26
1. Concept of Alzheimer's Disease and the Need for Early Biomarkers
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by neuropathological changes that manifest decades before clinical symptoms (e.g., memory loss, cognitive decline) appear. Core pathological features include amyloid-β (Aβ) plaque deposition and abnormal hyperphosphorylation of tau protein, which forms neurofibrillary tangles (NFTs). Early and accurate diagnosis is critical for timely intervention and clinical trial enrollment. Traditional diagnostic methods—such as cerebrospinal fluid (CSF) biomarker testing (e.g., Aβ42, p-tau) and positron emission tomography (PET) imaging—are limited by invasiveness (CSF collection) or high cost and poor accessibility (PET), hindering large-scale screening and dynamic disease monitoring. Thus, non-invasive, convenient, and low-cost blood-based biomarkers are urgently needed to enable early AD detection and progression tracking.
2. Research Frontiers
Phosphorylated tau (p-tau) proteins have emerged as promising AD biomarkers, with specific phosphorylation sites (e.g., p-tau181, p-tau217) showing diagnostic potential in blood. Among these, tau phosphorylated at threonine 231 (p-tau231) has gained attention due to its early elevation in CSF—appearing shortly after Aβ pathology onset, potentially earlier than other p-tau isoforms. However, plasma p-tau231 concentrations are extremely low (far below CSF levels), making reliable quantification a technical challenge with conventional methods like ELISA. Recent breakthroughs in ultrasensitive detection technologies, such as single-molecule array (Simoa) technology, have overcome this barrier, enabling accurate measurement of plasma p-tau231. Current research frontiers focus on validating p-tau231’s diagnostic performance across diverse cohorts, comparing it with existing biomarkers, and exploring its utility in early AD staging and therapeutic response monitoring.
3. Research Significance
Plasma p-tau231 holds transformative significance for AD research and clinical practice. As an early pathological signal, it can identify individuals in the preclinical stage of AD (Aβ-positive but cognitively normal), a critical window for intervention. Its non-invasive nature enables large-scale population screening, addressing the unmet need for accessible AD risk stratification. Additionally, p-tau231 correlates strongly with gold-standard biomarkers (CSF p-tau231, Aβ-PET) and pathological staging, providing a reliable surrogate for central nervous system (CNS) pathology. For drug development, p-tau231 can serve as a pharmacodynamic marker to evaluate the efficacy of tau-targeting therapies in clinical trials. Furthermore, p-tau231-specific antibodies are foundational to developing ultrasensitive detection assays, bridging basic research and clinical translation.
4. Related Mechanisms, Research Methods, and Product Applications
4.1 Why p-tau231 Stands Out as an Early Biomarker
Tau protein phosphorylation at different sites exhibits distinct kinetics and pathological relevance:
* p-tau231 is elevated in the early stages of AD, even before clinical symptoms, and responds to Aβ pathology earlier than p-tau181.
* It correlates with Braak neurofibrillary tangle staging (a measure of tau pathology severity) and declines in cognitive function, reflecting disease progression.
* Its early appearance in plasma makes it a potential marker for "incipient" AD pathology, enabling intervention before irreversible neuronal damage.
4.2 Ultrasensitive Simoa Technology for Plasma p-tau231 Quantification
Simoa technology, a digital immunoassay platform, enables reliable detection of ultra-low concentrations of p-tau231:
Core Principle: Isolates individual immune complexes in femtoliter-sized microwells for digital counting, achieving sensitivity over 1,000 times higher than conventional ELISA.
Assay Development: Relies on highly specific monoclonal antibody pairs—capture antibodies recognize p-tau231 (phosphorylated Thr231) and detection antibodies target the tau N-terminal region (biotin-conjugated).
Performance: Achieves a lower limit of quantification (LLOQ) of 0.25 pg/mL, with a 98.5% detection rate in clinical samples, enabling accurate measurement of plasma p-tau231.
4.3 Diagnostic Performance of Plasma p-tau231
Multiple independent cohort studies (discovery, memory clinic, primary care, neuropathological validation) confirm p-tau231’s diagnostic value:
Disease Differentiation: Plasma p-tau231 levels are significantly higher in AD dementia patients than in cognitively normal individuals, mild cognitive impairment (MCI) patients, and non-AD neurodegenerative disease patients.
Correlation with Gold Standards: Strong positive correlations with CSF p-tau231 and Aβ-PET burden, confirming it reflects CNS pathological changes.
Early Detection: Elevated in Aβ-PET positive/cognitively normal individuals and Braak stages I-II (very early tau pathology), while p-tau181 increases later (stages III-IV).
4.4 Core Value of p-tau231 Antibodies in Research and Translation
p-tau231 antibodies are indispensable for advancing AD biomarker research and clinical translation:
Assay Foundation: High-affinity, specific antibody pairs are critical for developing ultrasensitive Simoa or ELISA assays, determining specificity and detection limits.
Mechanistic Validation: Enable quantification of p-tau231 in plasma, CSF, and tissue samples, validating its role as an early biomarker and correlating it with pathology/clinical outcomes.
Clinical Translation: Serve as key components in diagnostic kits for standardized, reproducible p-tau231 detection in clinical settings.
4.5 Product Applications in AD Research and Drug Development
ANT BIO PTE. LTD.’s p-tau231 antibodies support diverse research and translational applications:
Early AD Diagnosis: Enable development of high-sensitivity detection reagents for differential diagnosis, disease staging, and monitoring.
Neuropathological Research: Facilitate analysis of p-tau231 distribution in brain tissues (via IHC/IF) and its correlation with cognitive dysfunction.
Preclinical Drug Evaluation: Serve as a pharmacodynamic marker in transgenic animal or cellular models to assess tau-targeting drug efficacy.
Disease Model Validation: Characterize tau phosphorylation progression in induced pluripotent stem cell (iPSC)-derived neurons or transgenic models.
5. Brand Mission
ANT BIO PTE. LTD. is dedicated to empowering global neuroscience research and neurodegenerative disease diagnostics through innovative, high-quality reagents. We strive to develop cutting-edge antibodies, proteins, kits, and detection tools that enable early detection, mechanistic exploration, and therapeutic development for Alzheimer's disease and other tauopathies. Our mission is to accelerate scientific discovery, improve patient outcomes, and reduce the global burden of neurodegenerative diseases by providing reliable, reproducible, and high-performance research solutions. With a commitment to excellence, innovation, and customer-centricity, we aim to be a trusted partner for researchers and clinicians advancing the frontiers of AD research and precision medicine.
6. Related Product List
| Product Code |
Product Name |
Host |
| S0B3220 |
Tau (phospho T231) Mouse Monoclonal Antibody
(SDT-202-2) |
Mouse |
| S0B3217 |
Tau (phospho T231) Recombinant Rabbit Monoclonal Antibody
(SDT-177-1) |
Rabbit |
| S0B3216 |
Tau (phospho T231) Recombinant Rabbit Monoclonal Antibody
(SDT-177-17) |
Rabbit |
| S0B0054 |
Tau (phospho T231) Recombinant Rabbit Monoclonal Antibody
(SDT-177-1) |
Rabbit |
Core Advantages of ANT BIO PTE. LTD.’s p-tau231 Antibodies
Exceptional Site Specificity: Rigorously validated via competitive inhibition and phosphorylation site mutant experiments, specifically recognizing p-tau231 with minimal cross-reactivity to non-phosphorylated tau or other p-tau isoforms.
High Affinity and Stability: Exhibit stable high binding affinity, delivering strong signals with low background in WB, IHC, IF, and ELISA. Strict quality control ensures minimal batch-to-batch variation, guaranteeing data consistency.
Multi-Platform Compatibility: Validated for use in WB (tissue/cell lysates), IHC (FFPE brain sections from humans, monkeys, mice), IF (co-localization studies), and ELISA (CSF/blood quantification assays).
7. AI Disclaimer
This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
|
中文
